Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)
Indication:
Bladder Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Bladder Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph2 DSP-7888+Bevacizumab GBM View
Description: A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy (BBI-DSP7888-201G)
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph2 DSP-7888+Bevacizumab GBM View
Description: A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy (BBI-DSP7888-201G)
Indication:
Brain Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
TALAZ IN GERMLINE BRCA1/2 MUT BC View
Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER
Indication:
Breast Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Colon Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Endometrial Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ublituximab+TGR-1202 Cross-over View
Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
Indication:
Leukemia
Location:
Austin Brain Tumor Center
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Tepotinib stage IIIB/IV NSCLC w/ METex14 View
Description: A Phase II single-arm trial to investigate tepotinib inadvanced (Stage IIIB/IV) non-small cell lung cancerwith MET exon 14 (METex14) skipping alterations or MET amplification (VISION): MS200095-0022
Indication:
Lung Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph2 MGCDs+Nivo NSCLC View
Description: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (MRTX-500)
Indication:
Lung Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph2 Poziotinib EGFR/HER2 NSCLC View
Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Lung Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Austin Brain Tumor Center
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Central
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-South Austin
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Round Rock
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
TGR-1202 +/- Ublituximab in NHL View
Description: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin''s Lymphoma (UTX-TGR-205)
Indication:
Lymphomas
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph2 R/R MCL (CITADEL-205) View
Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205
Indication:
Lymphomas
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph2 R/R MCL (CITADEL-205) View
Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205
Indication:
Lymphomas
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 R/R MCL (CITADEL-205) View
Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205
Indication:
Lymphomas
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph2 R/R MCL (CITADEL-205) View
Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph2 R/R MCL (CITADEL-205) View
Description: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)- INCB050465-205
Indication:
Lymphomas
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Melanoma
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Melanoma
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Melanoma
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Pancreatic Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
Ph 2 Nira + TSR-042 Plt Rst Ovarian View
Description: 3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Renal Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Renal Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Renal Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Solid Tumors
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Solid Tumors
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Ph1/2 AMG510 KRAS mut G12C Solid Tumors View
Description: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)
Indication:
Solid Tumors
Location:
Austin Brain Tumor Center
Phase: II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin North Suite 300
Phase: II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin North Suite 120
Phase: II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Austin Brain Tumor Center
Phase: II
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations(FIGHT-201)(INCB 54828-201)
Indication:
Urothelial Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Round Rock
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Midtown
Phase: II
Title:
Sitravatinib + Nivo Adv/Met Urothelial View
Description: A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Austin Brain Tumor Center
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Central
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Urothelial Cancer
Location:
Texas Oncology-South Austin
Phase: II
Title:
Ph2 Anti-PD1 INCMGA00012 Solid Tumors View
Description: INCMGA 0012-203: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Round Rock
Phase: II